



11-1-2017

Epigenetic suppression of hippocampal calbindin-D28k by Δ FosB drives seizure-related cognitive deficits.

Jason C. You

Thomas Jefferson University; Baylor College of Medicine, jason.you@jefferson.edu

Kavitha Muralidharan

Thomas Jefferson University; Baylor College of Medicine

Jin W. Park

Baylor College of Medicine

Iraklis Petrof

Thomas Jefferson University

Mark S. Pyfer

Thomas Jefferson University

See next page for additional authors

[Let us know how access to this document benefits you](#)

Follow this and additional works at: https://jdc.jefferson.edu/departement_neuroscience

 Part of the [Neurosciences Commons](#)

Recommended Citation

You, Jason C.; Muralidharan, Kavitha; Park, Jin W.; Petrof, Iraklis; Pyfer, Mark S.; Corbett, Brian F.; LaFrancois, John J.; Zheng, Yi; Zhang, Xiaohong; Mohila, Carrie A.; Yoshor, Daniel; Rissman, Robert A.; Nestler, Eric J.; Scharfman, Helen E.; and Chin, Jeannie, "Epigenetic suppression of hippocampal calbindin-D28k by Δ FosB drives seizure-related cognitive deficits." (2017). *Department of Neuroscience*. Paper 41.

https://jdc.jefferson.edu/departement_neuroscience/41

Authors

Jason C. You, Kavitha Muralidharan, Jin W. Park, Iraklis Petrof, Mark S. Pyfer, Brian F. Corbett, John J. LaFrancois, Yi Zheng, Xiaohong Zhang, Carrie A. Mohila, Daniel Yoshor, Robert A. Rissman, Eric J. Nestler, Helen E. Scharfman, and Jeannie Chin



Published in final edited form as:

Nat Med. 2017 November ; 23(11): 1377–1383. doi:10.1038/nm.4413.

Epigenetic suppression of hippocampal calbindin-D28k by FosB drives seizure-related cognitive deficits

Jason C. You^{1,2}, Kavitha Muralidharan^{1,2}, Jin W. Park², Iraklis Petrof¹, Mark S. Pyfer¹, Brian F. Corbett¹, John J. LaFrancois³, Yi Zheng², Xiaohong Zhang¹, Carrie A. Mohila⁴, Daniel Yoshor⁵, Robert A. Rissman⁶, Eric J. Nestler⁷, Helen E. Scharfman³, and Jeannie Chin^{1,2}

¹Department of Neuroscience and Farber Institute for Neurosciences, Thomas Jefferson University, Philadelphia, PA, USA

²Memory & Brain Research Center, Department of Neuroscience, Baylor College of Medicine, Houston, TX, USA

³Department of Neuroscience and Physiology and Department of Psychiatry, New York University School of Medicine, New York, NY, USA

⁴Department of Pathology, Texas Children's Hospital and Baylor College of Medicine, Houston, TX, USA

⁵Department of Neurosurgery, Baylor College of Medicine, Houston, TX, USA

⁶Department of Neurosciences, University of California San Diego School of Medicine, La Jolla, CA, USA and VA San Diego Healthcare System, San Diego, CA, USA

⁷Fishberg Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Abstract

The calcium-binding protein calbindin-D28k is critical for hippocampal function and cognition¹⁻³, but its expression is markedly decreased in various neurological disorders associated with epileptiform activity and seizures⁴⁻⁷. In Alzheimer's disease (AD) and epilepsy, both of which are accompanied by recurrent seizures⁸, the severity of cognitive deficits reflects the degree of calbindin reduction in the hippocampal dentate gyrus (DG)^{4,9,10}. However, despite the importance of calbindin in both neuronal physiology and pathology, the regulatory mechanisms that control its expression in the hippocampus are poorly understood. Here we report an epigenetic mechanism by which seizures chronically suppress hippocampal calbindin expression and impair cognition. We

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

Correspondence should be addressed to: Jeannie Chin, PhD, Memory & Brain Research Center, Department of Neuroscience, Baylor College of Medicine, Houston, TX 77030, Tel: 713-798-6407, Fax: 713-798-3946, Jeannie.Chin@bcm.edu.

Data availability: The data that support the findings of this study are available from the corresponding author upon request.

Author Contributions: JCY and JC conceived the project. JCY, XZ, EJM, HES, and JC designed the experiments. JCY, MSP, IP, KM, BFC, JJF, YZ, JWP, HES, and JC performed the experiments and analyzed the data. CAM and DY collected and analyzed specimens derived from human epilepsy patients. RAR provided fixed AD brain samples and clinical information. All authors discussed results and JCY, RAR, HES, and JC wrote the manuscript.

Authors report no competing financial interests or conflicts.

demonstrate that FosB, a highly stable transcription factor, is induced in the hippocampus of mouse models of AD and seizures, where it binds and triggers histone deacetylation at the calbindin gene (*Calb1*) promoter, and downregulates *Calb1* transcription. Notably, increasing DG calbindin levels, either by direct virus-mediated expression or inhibition of FosB signaling, improves spatial memory in a mouse model of AD. Moreover, levels of FosB and calbindin expression are inversely related in DG of patients with temporal lobe epilepsy (TLE) or AD, and correlate with performance on the Mini-Mental State Examination (MMSE). We propose that chronic suppression of calbindin by FosB is one mechanism by which intermittent seizures drive persistent cognitive deficits in conditions accompanied by recurrent seizures.

Expression of calbindin-D28k in the hippocampal DG is indicative of cognitive function in both patients and mouse models of AD and epilepsy^{4,9-12}. In addition, calbindin knockdown/knockout animals exhibit impaired synaptic plasticity and spatial memory^{1-3,13,14}. These findings highlight calbindin's role as a critical regulator of neuronal calcium signaling and hippocampal function¹⁵. However, little is known about the regulatory mechanisms that modulate calbindin expression in normal or pathologic conditions. Considering how crucial calbindin is for synaptic function and cognition^{1-3,13,14}, elucidating these mechanisms is essential as it may aid the development of novel therapeutics to ameliorate cognitive deficits in AD and other disorders associated with seizures.

To identify mechanisms that control hippocampal calbindin expression, we examined long-term gene regulation in the hippocampus of a transgenic AD mouse model expressing mutant human amyloid precursor protein (APP)¹⁶. APP mice of both sexes were examined at 2-4 months of age, an age when they begin to exhibit spontaneous recurrent seizures and cognitive deficits similar to AD patients, but prior to plaque deposition¹⁶⁻¹⁹. By immunohistochemical analysis, we found that hippocampal calbindin expression was lower in APP mice compared to non-transgenic littermates (NTG), and that levels of calbindin expression inversely correlated with the frequency of electroencephalographic (EEG) seizures (Fig. 1a,b), similar to patients with seizures^{5,10}. Notably, even APP mice with relatively infrequent seizures exhibited reduced calbindin expression, suggesting that downregulation of hippocampal calbindin was mediated by long-lasting, activity-dependent mechanisms. After surveying the literature to determine what activity-dependent factors might regulate calbindin expression over extended periods of time, we focused on FosB, a truncated splice variant of the transcription factor FosB. FosB is a unique activity-dependent immediate early gene (IEG) product, possessing an unusually long half-life (~8 days) that allows it to exert persistent control over neuronal gene expression²⁰. The actions of FosB in epigenetic gene regulation are well studied in the nucleus accumbens^{20,21}, and a recent study suggests that it may also have functions in the hippocampus²². We found that seizures were associated with elevated hippocampal expression of FosB, and higher levels of FosB expression were correlated with lower calbindin expression in APP mice (Fig. 1b,c). Therefore, we hypothesized that FosB is a key regulatory factor involved in the suppression of calbindin following epileptiform activity in AD and other seizure-associated disorders.

To test this hypothesis, we performed a promoter analysis of *Calb1* to identify potential regulatory regions where FosB might bind. Our analysis revealed a region 320 bp upstream of the transcription start site containing cAMP and TPA response elements (CRE and TRE, respectively) in close proximity to one another (Supplemental Fig. 1a). Since both elements are known to recruit IEG proteins²³, we performed chromatin immunoprecipitation (ChIP) on hippocampal tissue from APP as well as NTG mice to test whether FosB enrichment occurred at this promoter region. Indeed, ChIP results confirmed binding of FosB to the promoter of *Calb1*, and FosB enrichment at this site was greater in APP mice relative to NTG littermates (Fig. 1d). FosB enrichment on *Calb1* was validated by comparison to IgG control ChIP and promoter amplicon sequencing (Supplemental Fig. 1b,c). These data highlight the potential ability of FosB to regulate calbindin expression via actions at the *Calb1* promoter gene.

We therefore assessed whether FosB binding to *Calb1* was associated with chromatin modifications that would impact *Calb1* expression. Previous studies have demonstrated that reduction of calbindin protein levels in AD and epilepsy patients and rodent models occurs downstream of mRNA reduction^{4,7,9,24}. In line with these findings, FosB binds histone deacetylase 1 (HDAC1)²¹, suggesting that it suppresses *Calb1* transcription via histone deacetylation. Indeed, we found hypoacetylated histone 4 lysine residues on the *Calb1* promoter in APP mice relative to NTG controls (Fig. 1e and Supplemental Fig. 2a,b). We did not detect changes in acetylation on histone 3. Because long-term histone hypoacetylation can trigger histone methylation to further suppress gene expression^{21,25}, we also assessed histone methylation at the *Calb1* promoter. We found that the *Calb1* promoter was hypermethylated in APP mice at histone 4 lysine 20, but not histone 3 lysine 9 (Fig. 1f and Supplemental Fig. 2c-e). Together, these results demonstrate *Calb1* regulation by specific histone 4 modifications.

The activity-driven nature of FosB expression²⁰ and prevalence of calbindin reduction across many disorders accompanied by seizures^{4-7,9,10} suggest that epigenetic regulation of *Calb1* by FosB occurs in not just APP mice but also other rodent models with seizures. Therefore, we examined the relationship between FosB and calbindin in a mouse model of epilepsy in which severe seizures lasting several hours (status epilepticus) are induced by pilocarpine. Similar to APP mice, we found elevated binding of FosB to the *Calb1* promoter, and lower *Calb1* promoter histone 4 acetylation, in pilocarpine-treated mice relative to saline-treated controls (Fig. 1g,h and Supplemental Fig. 3a,b). Moreover, DG granule cells in pilocarpine-treated mice exhibited higher FosB and lower calbindin protein expression that was evident on a cell-by-cell basis (Fig. 1i). The inverse relationship between FosB and calbindin was also evident on a cell-by-cell basis in APP mice (Fig. 1j).

To demonstrate that a reduction in calbindin expression can be a direct result of FosB-mediated epigenetic regulation, we tested whether adenoassociated virus (AAV)-mediated overexpression of FosB in the hippocampus of wild-type C57BL/6 mice (AAV-FosB mice) could suppress calbindin expression. Virus carrying CMV promoter-driven FosB/eGFP or eGFP alone was stereotaxically infused into the DG of wild-type C57BL/6 mice (see Methods). This infusion resulted in robust FosB and eGFP expression throughout the rostral-caudal extent of the DG (Fig. 2a,b and Supplemental Figs. 4,5). Viral overexpression

of FosB in wild-type mice did not affect neuronal survival or expression of neuron-specific genes such as NeuN (Supplemental Fig. 4c,e), and there was no detectable epileptiform activity in the hippocampus (Supplemental Fig. 6). Notably, FosB overexpression did enhance the binding of FosB to *Calb1* (Fig. 2c and Supplemental Fig. 3c), and triggered *Calb1* promoter histone 4 deacetylation (Fig. 2d and Supplemental Fig. 3d), consistent with its ability to recruit HDAC1 to gene promoters²¹. Furthermore, we found lower levels of calbindin mRNA and protein in the DG of AAV- FosB mice (Fig. 2e-h). Reduced calbindin protein expression was apparent in both molecular and granule cell layers of the DG, reflecting the dendrites and cell bodies of granule cells, respectively (Supplemental Fig. 7a-d). Overall, these results demonstrate direct epigenetic control of *Calb1* by FosB. We also found that FosB overexpression was sufficient to suppress granule cell expression of cFos, another gene target of FosB (Supplemental Fig. 7e,f and²¹). These findings are consistent with prior studies showing that cFos expression in granule cells is increased acutely, but decreased chronically, by seizures²⁶.

To determine whether FosB-mediated gene changes directly impact cognition, we tested spatial memory in AAV- FosB mice using the object location test. This test is hippocampus-dependent²⁷, and has previously been used to demonstrate spatial memory impairments in mouse models of AD and epilepsy^{28,29}. We found that overexpression of FosB in the hippocampus was sufficient to impair spatial memory (Fig. 2i).

To demonstrate that FosB is not only sufficient but also necessary for regulating hippocampal calbindin expression and memory function, we tested whether inhibition of FosB signaling in APP mice could normalize calbindin expression and ameliorate spatial memory deficits. To block FosB signaling, we infused AAV carrying JunD/eGFP into the DG of APP mice. JunD is a truncated mutant of the transcription factor JunD, a predominant endogenous binding partner of FosB in the brain²⁰. This truncation removes the transactivation domain of JunD while leaving its dimerization and DNA-binding domains intact³⁰. Therefore, dimerization of JunD with FosB inhibits FosB in a dominant negative fashion. Notably, consistent with its truncation, JunD does not preclude FosB from binding its gene targets, but instead prevents the interaction of FosB with downstream transcriptional co-regulators at target gene promoters^{20,30}. Expression of JunD in different brain regions effectively antagonizes FosB-mediated gene regulation^{20,31}. Using the object location test, we found that expression of JunD in the hippocampus improved spatial memory in APP mice (Fig. 3a). We also demonstrate that FosB is required for epigenetic suppression of *Calb1* in APP mice, since JunD expression restored *Calb1* promoter histone acetylation (Fig. 3b and Supplemental Fig. 3e) and improved calbindin protein expression in the DG (Fig. 3c,d). Given that JunD-mediated amelioration of spatial memory in APP mice was accompanied by improved calbindin expression, we then asked whether direct restoration of hippocampal calbindin expression in APP mice could also improve memory. To bypass endogenous control of *Calb1* by FosB, we infused AAV carrying CMV promoter-driven calbindin/eGFP into the hippocampus to elevate calbindin expression in APP mice (Fig. 3e,f). We found that directly elevating hippocampal expression of calbindin in APP mice improved object location memory (Fig. 3g), similar to hippocampal JunD expression.

Our findings in APP mice suggest that regulation of calbindin by FosB may be a potential therapeutic target in AD and other seizure-associated disorders. To determine whether the relationship between FosB and calbindin also exists in human patients, we examined expression patterns of both proteins in the DG of patients diagnosed with mild cognitive impairment (MCI) or AD. Indeed, higher FosB expression corresponded with lower calbindin expression in MCI and AD patients (Fig. 4a-d), similar to APP mice. In addition, we observed a correlation between levels of both proteins and MMSE scores in MCI but not AD patients, presumably because of the numerous deficits in AD relative to MCI (Fig. 4e-h). There was also a significant correlation between FosB or calbindin expression and MMSE scores when all patients (control, MCI, AD) were analyzed together (Supplemental Figs. 8 and 9). Lastly, to determine whether the relationship between FosB and calbindin expression also exists in non-AD related conditions in which recurrent seizures occur, we examined DG tissue resected from TLE patients. Consistent with findings in MCI and AD patients, we observed an inverse relationship between FosB and calbindin expression in TLE patients (Fig. 4i,j).

In summary, we have discovered a novel regulatory mechanism in which epileptiform activity recruits FosB to epigenetically suppress calbindin expression in the DG. In doing so, we highlight FosB's role as a transcription factor capable of chronically suppressing a gene that regulates synaptic transmission, plasticity, cognition, and seizure-related pathology. Given the prevalence of seizures across various disorders such as autism and schizophrenia^{32,33} in addition to epilepsy and AD, the identification of FosB's role in the hippocampus may have broad implications for understanding why cognitive deficits are comorbidities of many disorders accompanied by seizures. Furthermore, nuclear accumulation of FosB due to its unusually long half-life provides a mechanism to explain why cognitive deficits persist even during seizure-free periods. Our finding that elevated FosB expression correlates with reduced calbindin expression in both AD and TLE patients suggests that patients and rodent models of human disease share similar mechanisms of epigenetic regulation induced by seizures. By restoring memory function in APP mice either via FosB inhibition or virus-driven calbindin expression, we have identified a molecular pathway that can potentially be targeted to improve cognition in AD and other seizure-associated disorders. Moreover, our finding that alterations in FosB and calbindin expression correlate with MMSE scores in MCI, but not AD, patients suggests that possible therapeutic interventions targeting either protein should be initiated as early as possible to maximize effectiveness. The association of MMSE scores with FosB and calbindin in MCI patients might be explained by the fact that hippocampal dysfunction, to which alterations in FosB and calbindin expression greatly contribute, is particularly prominent in early disease. However, as AD progresses, disease pathophysiology in additional brain areas also contributes to overall cognitive dysfunction. The results of our study are consistent with a growing body of evidence showing that seizures occurring in early stages of AD impair memory and exacerbate cognitive decline^{18,19}. The prevalence of seizures in AD may also be much greater than previously thought, as routine scalp EEG has been shown to miss "silent" hippocampal seizures detected via foramen ovale electrodes in AD patients³⁴. Finally, some evidence suggests that calbindin reduction in granule cells following epileptiform activity may confer neuroprotection against excitotoxicity^{35,36} (but also

see^{37,38}). Demonstration of calbindin suppression by FosB may provide further support for a neuroprotective role of calbindin reduction in granule cells, since previous studies have shown that both FosB and HDAC1 can protect neurons from neurotoxic injury^{39,40}. Interestingly however, we did not find obvious neuronal loss when we blocked FosB signaling or virally expressed calbindin in APP mice (see Fig. 3d,f), which may be related to the time frame of our experiments or the possible existence of redundant neuroprotective mechanisms. Regardless, a potential trade-off between neuroprotection and synaptic function may emphasize caution for therapeutics targeting either pathway, as efforts to augment one pathway may generate side effects by simultaneously altering the other. To validate the therapeutic potential of targeting FosB and/or calbindin, future studies will need to further characterize their functions in the hippocampus.

Methods

Mice

Heterozygous APP transgenic mice expressing human APP carrying the Swedish (K670N, M671L) and Indiana (V717F) familial AD mutations (hAPP770 numbering) driven by the platelet-derived growth factor (PDGF) β chain promoter (Line J20)¹⁶ were used in this study. The line was crossed for >10 generations onto a C57BL/6 background, and heterozygosity was maintained by breeding with wild-type C57BL/6 mice from The Jackson Laboratory (Bar Harbor, ME). Male and female mice from this line were used for experiments, and were evaluated at 2-4 months of age. At this age, many APP mice exhibit both recurrent seizures and cognitive deficits, but no plaque deposits¹⁷. Age- and sex-matched nontransgenic (NTG) wild-type animals from the same line were used as controls.

Wild-type C57BL/6 mice from The Jackson Laboratory were used at 2-4 months of age for AAV- FosB overexpression experiments (see AAV-mediated gene transfer). Wild-type C57BL/6 mice from Charles River Laboratories (Wilmington, MA) were used at 2 months of age for pilocarpine experiments (see Pilocarpine-induced seizures).

For sacrifice, mice were anesthetized and perfused transcardially with PBS. Hemibrains were either fixed by immersion in 4% phosphate-buffered paraformaldehyde and sectioned at 30 μ m (in preparation for *in situ* hybridization or immunohistochemistry) or frozen at -80°C (for chromatin immunoprecipitation). All procedures were approved by the Institutional Animal Care and Use Committees of Thomas Jefferson University, Baylor College of Medicine, and The Nathan Kline Institute.

Pilocarpine-induced seizures

Mice were initially administered scopolamine methyl nitrate (2 mg/kg sc; Sigma-Aldrich) and terbutaline hemisulfate salt (2 mg/kg sc; Sigma-Aldrich) to block peripheral effects of pilocarpine and dilate the respiratory tract, respectively. They also received 150 mg/kg ethosuximide sc (Sigma-Aldrich), as we have found that it improved mortality in C57BL/6 mice⁴¹. Thirty min later, pilocarpine hydrochloride (260 mg/kg sc; Sigma-Aldrich) was administered, and mice were placed in a standard mouse cage without bedding on a heating pad set at 37°C. Acute seizures were behaviorally monitored using a modified Racine's

scale: stage 1, mouth and facial movement; stage 2, head nodding; stage 3, rearing with unilateral forelimb tonic-clonic movements; stage 4, rearing with bilateral forelimb tonic-clonic movements; stage 5, rearing and falling with tonic-clonic movements of the forelimbs. Once status epilepticus began (defined by the first stage 3-5 seizure that was not followed by resumption of normal behavior), mice were placed in a new cage at room temperature for 2 hrs and returned to the heated cage after seizure activity was reduced with diazepam (10 mg/kg sc; Henry Schein). Mice were then administered 5% dextrose-lactated Ringer's solution (1 mL ip; Henry Schein) while sedated by diazepam. After 2 hrs animals were then returned to the home cage, which was placed on the heating pad until sacrifice 3 days later.

Human tissue

Fixed dentate gyrus samples from AD and MCI patients were obtained from the Alzheimer's Disease Research Center at the University of California San Diego (San Diego, CA), sectioned at 60 μ m, and stained for FosB and calbindin (see Diaminobenzidine staining) after antigen retrieval with citrate buffer and formic acid. Fixed dentate gyrus samples from temporal lobe epilepsy patients were obtained and used with informed consent under IRB protocol H-10255, using epilepsy surgery resection specimens derived from adult patients treated at Baylor College of Medicine (Houston, TX). Sections were deparaffinized, subjected to antigen retrieval as above, and then stained for FosB and calbindin.

AAV-mediated gene transfer

AAV serotype 2 carrying CMV- JunD-IRES2-eGFP (AAV- JunD), CMV- FosB-IRES2-eGFP (AAV- FosB), or CMV-eGFP (AAV-eGFP) was developed and characterized by the Nestler lab²⁰. Previous experiments demonstrate that AAV2 is neurotropic and achieves stable neuronal gene expression within 18-22 days of infusion into the brain. The presence of IRES2 in AAV- FosB and AAV- JunD allows independent expression of FosB or JunD and eGFP, although there is preferential expression of the gene closest to the promoter. AAV serotype 2 carrying CMV-mCalb1-IRES2-eGFP (AAV-Calb1) was synthesized by Vector Biolabs (Philadelphia, PA).

One μ L of virus solution was stereotaxically infused unilaterally or bilaterally into the hippocampus at rostral (-1.7 mm A/P, 1.2 mm M/L, 2 mm D/V from bregma) and caudal (-2.7 mm A/P, 2 mm M/L, 2.1 mm D/V from bregma) coordinates. Approximately 2×10^8 infectious particles were infused into each hippocampus. Mice were allowed to recover for 22-28 days post-surgery before further experimentation or sacrifice. Virus expression was assessed in all mice. Mice that did not exhibit expression in the hippocampus were excluded from analysis.

Object location

Object location is a dentate gyrus-dependent spatial memory test²⁷ that requires that mice learn and remember the positions of two objects in an arena. Extra-arena spatial cues exist to help orient the mice during the train and test phases. For training, two identical flasks were placed at adjacent far corners of the arena (Fig. 2h), and animals were allowed to explore both flasks in 3 blocks of 3 min each with 3 min breaks in between. The amount of time

mice spent exploring each flask was recorded by the experimenter. After a delay of 2 hrs, mice were returned to the arena for the test phase. In this phase, we displaced one flask to the adjacent empty corner, causing the two flasks to be diagonal from one another. Mice were given 3 minutes to explore both flasks, and the amount of time spent exploring each flask was recorded. Mice that remember the original locations of the two flasks will spend more time exploring the displaced flask vs. the non-displaced flask during the test phase. Previous studies have shown that both animal models of AD and epilepsy are impaired in this task^{28,29}.

Electroencephalogram (EEG) recording

Mice were stereotaxically implanted with a 6-electrode array headcap for EEG monitoring: Two EEG screws were placed bilaterally over the left and right frontal cortices (AP: +1.5, ML: +/- 1.4), and a depth electrode was placed in right hippocampus (AP: -2.2, ML: -2, DV: -1.8). In addition, a reference screw and a depth ground electrode were placed over and inside cerebellum, respectively. Finally, an EEG screw was placed over parietal cortex (AP: -2.2, ML: -2) for additional anchor. All EEG screws were wrapped with silver wires connected to a pedestal (Plastics One, Roanoke, VA), and the entire assembly was secured on the skull with dental cement (Ortho-Jet, LangDental, Wheeling, IL). Animals were allowed to recover for at least 4 days prior to commencement of recordings.

For EEG recordings, a flexible cable connected the animals' headcaps to a commutator thus allowing them to move freely during the recordings. Video-monitored EEG recordings were performed in the animals' home cage using a Stellate Harmonie (Natus Medical, Pleasanton, CA) interface. Spike count analysis was performed using LabChart Pro (AD Instruments, Dunedin, NZ).

Chromatin immunoprecipitation (ChIP)

Whole hippocampi were subdissected, fixed in 1% formaldehyde for 15 min, and homogenized in a 0.5% NP40 cell lysis buffer using Potter-Elvehjem PTFE tissue grinders. Nuclei were subsequently pelleted and reconstituted in 1% SDS. Nuclear lysis was accomplished via repetitive freeze-thaw, and chromatin shearing followed via the Digital SLP probe sonifier (Branson Ultrasonics) or Q800R bath sonicator (QSonica). Both methods of sonication were calibrated to produce fragment sizes 100-600 bp (with a primary peak at 200 bp), detected via ethidium bromide gel. Afterwards, ChIP was performed using the Magna ChIP A Kit (Millipore). ChIP antibodies were used at 2 μ g, and included rabbit anti-FosB (Cell Signaling 9890 and D3S8R), rabbit anti-H3K9+K14+K18+K23+K27ac (Abcam ab47915), rabbit anti-H4K5+K8+K12+K16ac (Millipore 06-866), rabbit anti-H3K9me2 (Abcam ab1220), rabbit anti-H3K9me3 (Millipore 07-442), rabbit anti-H4K20me3 (Millipore 07-463), and normal rabbit IgG (Millipore 12-370). Prior to the addition of antibody, 2% of the sheared chromatin was set aside as input. Following ChIP, immunoprecipitated chromatin was eluted using 0.1M NaHCO₃ and 1% SDS. Next, protein was digested using 0.1 mg/mL proteinase K, and DNA was separated using phenol-chloroform extraction. DNA was then pelleted and washed twice using 70% ethanol, and reconstituted in MilliQ H₂O. *Calb1* promoter enrichment was analyzed using qPCR of ChIP DNA versus input. Primers for *Calb1* promoter amplification are as follows: 5'-

TTCAAATACTCAACTGCCTCG-3' (forward) and 5'-
GGAGGCTTTCACCTCCTGAATGT-3' (reverse).

Diaminobenzidine (DAB) staining

Brain sections were avidin-biotin/immunoperoxidase labeled using the following primary antibodies: rabbit anti- FosB (1:300, Cell Signaling 9890), rabbit anti-calbindin (1:15,000, Swant CB-38A), rabbit anti-JunD (1:1000, Santa Cruz Biotechnology sc-74). Biotinylated goat anti-rabbit (1:200, Vector BA-1000) was used as the secondary antibody. DAB was used as the chromagen. For analysis of immunoreactive (IR) structures, two coronal sections (300 μm apart) were selected per mouse between -2.54 and -2.88 mm from bregma. The integrated optical density (IOD) of immunostains was determined using the MetaMorph Image Analysis Software (Molecular Devices) and averaged in two areas (0.04 mm^2 each) of either the molecular (calbindin) or granule cell layer (FosB) of the dentate gyrus (DG) and stratum radiatum of CA1. Relative IR was thus expressed as the IOD ratio in the DG versus CA1. The mean ratio of nontransgenic (NTG) mice was defined as 1. For quantification of FosB and calbindin in fixed human dentate gyrus, IR values were background corrected using comparison with nonspecific staining in a nearby acellular white matter tract.

Immunofluorescence staining

All brain sections within an experiment were processed, stained, and imaged at the same time, with the same parameters. Brain sections were fluorescently labeled using the following primary antibodies: rabbit anti- FosB (1:100, Cell Signaling 9890; 1:1000, Cell Signaling D3S8R), mouse anti-calbindin (1:1000, Swant 300), mouse anti-NeuN (1:5000, Millipore MAB377), goat anti-cFos (1:300, Santa Cruz Biotechnology sc-52g). Fluorophore-conjugated secondary antibodies utilized in this study included donkey anti-rabbit AMCA (1:200, Jackson ImmunoResearch 711-155-152), donkey anti-goat Cy3 (1:200, Jackson ImmunoResearch 705-165-147), donkey anti-mouse Alexa Fluor 594 (1:500, Life Technologies A-21203), donkey anti-rabbit Alexa Fluor 488 (1:500, Life Technologies A-21206). For analysis of calbindin-IR, FosB-IR, and NeuN-IR structures, fluorescence intensity (FI) was determined in the DG molecular (calbindin) or granule cell layer (FosB, NeuN, and calbindin) in every 10th serial coronal section throughout the rostral-caudal extent of the hippocampus using MetaMorph Image Analysis Software. FI of CA1 stratum radiatum was obtained in the same sections. Relative IR was expressed as the FI ratio in the DG versus CA1. The mean ratio of NTG mice was defined as 1. For analysis of cFos-IR, fluorescently labeled cells were counted in the granule cell layer in every 10th serial coronal section throughout the rostral-caudal extent of the hippocampus. For cell-by-cell analysis of FosB-IR and calbindin-IR, FosB and calbindin FI were determined for individual cells via ImageJ (NIH). Random blocks of 8-10 adjacent cells from rostral hippocampal sections (-1.6 mm from bregma) of APP and pilocarpine-treated mice were chosen for quantification. The mean FI for both proteins was defined as 1.

In situ hybridization (ISH)

All solutions used to process brain sections designated for ISH were pretreated with DEPC and/or autoclaved to minimize RNA degradation. Non-sterile tools and surfaces were also pretreated with RNase Zap (Ambion). ISH-competent free-floating brain sections were

digested with 1 ug/mL proteinase K for 12 min before overnight hybridization at 65°C with digoxigenin-labeled full-length antisense riboprobe for mouse *Calb1* (synthesized from *Calb1* cDNA, IMAGE cat# MMM1013-202766730). Sense and no probe controls were included. The sections were then washed once with 5× SSC/0.5% Tween20 and 7 times with 0.2× SSC/0.5% Tween20. This is followed by blocking with 10% heat-inactivated sheep serum and overnight incubation with 1:5000 alkaline phosphatase-conjugated sheep anti-digoxigenin antibody (Roche 11333089001) at 4°C. Development a blue/purple stain for colorimetric detection was achieved via incubation with the chromogen NBT/BCIP (Roche) for 3 hrs at room temperature. Sections were then washed in PBS/EDTA and fixed with 4% paraformaldehyde for 10 min before mounting onto slides. Determination of *Calb1* mRNA signal was performed via IOD analysis of the DG granule cell layer, similar to IOD analysis for DAB staining.

Statistics

Statistical analyses were performed using SPSS-23 (IBM) and Prism 7 (GraphPad). Sample sizes for both biochemical and behavioral experiments were determined based on calculations performed on empirical data and power analyses. The number of animals used for each experiment was appropriate to detect biochemical or behavioral differences with 80% power and alpha set at 0.05. Unless otherwise stated, results are represented as sample means ± standard errors of the mean. These data are distributed normally as stipulated by the central limit theorem. Differences between experimental groups were assessed by Student's t-test (two-tailed except where indicated as one-tailed) when comparing means between two groups, paired t-test when comparing means within the same individuals, one-way ANOVA when comparing means between three or more groups, two-way ANOVA when performing multifactorial analyses, and the Welch's F test when data failed the Levene's test for homogeneity of variances. Post-hoc analyses were used where appropriate. Correlations were assessed by simple regression analysis. No specific method of randomization was used, but animals were semi-randomly assigned to experimental groups based on birth order after balancing for age, sex, and genotype. We found no differences in the FosB/calbindin relationship between male and female mice, therefore both sexes were included in experiments (FosB two-way ANOVA: genotype $F_{1,55}=24.41$, *** $p<0.0001$; sex $F_{1,55}=0.39$, $p=0.53$; interaction $F_{1,55}=1.35$, $p=0.25$; calbindin two-way ANOVA: genotype $F_{1,55}=48.78$, *** $p<0.0001$; sex $F_{1,55}=0.049$, $p=0.83$; interaction $F_{1,55}=0.0014$, $p=0.97$). For all analyses, the experimenters were blinded to the genotype and treatment type of each mouse. *In vivo* and ChIP experiments were replicated at least once, immunohistochemical experiments were replicated at least twice.

Further detailed information on experimental design and reagents can be found in the Life Sciences Reporting Summary.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Dr. Rohan Jagirdar for helpful comments on the manuscript. This work was supported by the Margaret Q. Landenberger Research Foundation (JC), the Hassel Family Foundation (JC), National Institutes of Health Grants NS085171 (JC), F30-AG048710 (JCY), NYS OMH (HES, JJJ), and AG051848, BX003040, AG0051839, AG005131 (RAR).

References

1. Westerink RH, Beekwilder JP, Wadman WJ. Differential alterations of synaptic plasticity in dentate gyrus and CA1 hippocampal area of Calbindin-D28K knockout mice. *Brain Res.* 2012; 1450:1–10. [PubMed: 22405690]
2. Molinari S, et al. Deficits in memory and hippocampal long-term potentiation in mice with reduced calbindin D28K expression. *Proc Natl Acad Sci U S A.* 1996; 93:8028–8033. [PubMed: 8755597]
3. Jouvenceau A, et al. Decrease in calbindin content significantly alters LTP but not NMDA receptor and calcium channel properties. *Neuropharmacology.* 2002; 42:444–458. [PubMed: 11955516]
4. Emmanuele V, et al. Decreased hippocampal expression of calbindin D28K and cognitive impairment in MELAS. *J Neurol Sci.* 2012; 317:29–34. [PubMed: 22483853]
5. Abraham H, et al. Degree and pattern of calbindin immunoreactivity in granule cells of the dentate gyrus differ in mesial temporal sclerosis, cortical malformation- and tumor-related epilepsies. *Brain Res.* 2011; 1399:66–78. [PubMed: 21621747]
6. Magloczky Z, Halasz P, Vajda J, Czirjak S, Freund TF. Loss of Calbindin-D28K immunoreactivity from dentate granule cells in human temporal lobe epilepsy. *Neuroscience.* 1997; 76:377–385. [PubMed: 9015323]
7. Iacopino AM, Christakos S. Specific reduction of calcium-binding protein (28-kilodalton calbindin-D) gene expression in aging and neurodegenerative diseases. *Proc Natl Acad Sci U S A.* 1990; 87:4078–4082. [PubMed: 2140897]
8. Chin J, Scharfman HE. Shared cognitive and behavioral impairments in epilepsy and Alzheimer's disease and potential underlying mechanisms. *Epilepsy Behav.* 2013; 26:343–351. [PubMed: 23321057]
9. Palop JJ, et al. Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. *Proc Natl Acad Sci U S A.* 2003; 100:9572–9577. [PubMed: 12881482]
10. Karadi K, et al. Correlation between calbindin expression in granule cells of the resected hippocampal dentate gyrus and verbal memory in temporal lobe epilepsy. *Epilepsy Behav.* 2012; 25:110–119. [PubMed: 22796338]
11. Hall AM, et al. Tau-dependent Kv4.2 depletion and dendritic hyperexcitability in a mouse model of Alzheimer's disease. *J Neurosci.* 2015; 35:6221–6230. [PubMed: 25878292]
12. Sanchez PE, et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. *Proc Natl Acad Sci U S A.* 2012; 109:E2895–2903. [PubMed: 22869752]
13. Klapstein GJ, et al. Calbindin-D28k fails to protect hippocampal neurons against ischemia in spite of its cytoplasmic calcium buffering properties: evidence from calbindin-D28k knockout mice. *Neuroscience.* 1998; 85:361–373. [PubMed: 9622236]
14. Jouvenceau A, et al. Glutamatergic synaptic responses and long-term potentiation are impaired in the CA1 hippocampal area of calbindin D(28k)-deficient mice. *Synapse.* 1999; 33:172–180. [PubMed: 10420165]
15. Brini M, Cali T, Ottolini D, Carafoli E. Neuronal calcium signaling: function and dysfunction. *Cell Mol Life Sci.* 2014; 71:2787–2814. [PubMed: 24442513]
16. Mucke L, et al. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. *J Neurosci.* 2000; 20:4050–4058. [PubMed: 10818140]

17. Palop JJ, et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. *Neuron*. 2007; 55:697–711. [PubMed: 17785178]
18. Vossel KA, et al. Incidence and impact of subclinical epileptiform activity in Alzheimer's disease. *Ann Neurol*. 2016; 80:858–870. [PubMed: 27696483]
19. Vossel KA, et al. Seizures and epileptiform activity in the early stages of Alzheimer disease. *JAMA Neurol*. 2013; 70:1158–1166. [PubMed: 23835471]
20. Robison AJ, Nestler EJ. Transcriptional and epigenetic mechanisms of addiction. *Nat Rev Neurosci*. 2011; 12:623–637. [PubMed: 21989194]
21. Renthal W, et al. Delta FosB mediates epigenetic desensitization of the c-fos gene after chronic amphetamine exposure. *J Neurosci*. 2008; 28:7344–7349. [PubMed: 18632938]
22. Eagle AL, et al. Experience-Dependent Induction of Hippocampal DeltaFosB Controls Learning. *J Neurosci*. 2015; 35:13773–13783. [PubMed: 26446228]
23. Hai T, Curran T. Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity. *Proc Natl Acad Sci U S A*. 1991; 88:3720–3724. [PubMed: 1827203]
24. Carter DS, Harrison AJ, Falenski KW, Blair RE, DeLorenzo RJ. Long-term decrease in calbindin-D28K expression in the hippocampus of epileptic rats following pilocarpine-induced status epilepticus. *Epilepsy Res*. 2008; 79:213–223. [PubMed: 18394865]
25. Jenuwein T, Allis CD. Translating the histone code. *Science*. 2001; 293:1074–1080. [PubMed: 11498575]
26. Peng Z, Houser CR. Temporal patterns of fos expression in the dentate gyrus after spontaneous seizures in a mouse model of temporal lobe epilepsy. *J Neurosci*. 2005; 25:7210–7220. [PubMed: 16079403]
27. Kesner RP, Taylor JO, Hoge J, Andy F. Role of the dentate gyrus in mediating object-spatial configuration recognition. *Neurobiol Learn Mem*. 2015; 118:42–48. [PubMed: 25464012]
28. Cho KO, et al. Aberrant hippocampal neurogenesis contributes to epilepsy and associated cognitive decline. *Nat Commun*. 2015; 6:6606. [PubMed: 25808087]
29. Ma T, et al. Suppression of eIF2alpha kinases alleviates Alzheimer's disease-related plasticity and memory deficits. *Nat Neurosci*. 2013; 16:1299–1305. [PubMed: 23933749]
30. Brown PH, Kim SH, Wise SC, Sabichi AL, Birrer MJ. Dominant-negative mutants of cJun inhibit AP-1 activity through multiple mechanisms and with different potencies. *Cell Growth Differ*. 1996; 7:1013–1021. [PubMed: 8853897]
31. Berton O, et al. Striatal overexpression of DeltaJunD resets L-DOPA-induced dyskinesia in a primate model of Parkinson disease. *Biol Psychiatry*. 2009; 66:554–561. [PubMed: 19481198]
32. Zoghbi HY, Bear MF. Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities. *Cold Spring Harb Perspect Biol*. 2012; 4
33. Hesdorffer DC, et al. Epilepsy, suicidality, and psychiatric disorders: a bidirectional association. *Ann Neurol*. 2012; 72:184–191. [PubMed: 22887468]
34. Lam AD, et al. Silent hippocampal seizures and spikes identified by foramen ovale electrodes in Alzheimer's disease. *Nat Med*. 2017; 23:678–680. [PubMed: 28459436]
35. Nagerl UV, et al. Surviving granule cells of the sclerotic human hippocampus have reduced Ca(2+) influx because of a loss of calbindin-D(28k) in temporal lobe epilepsy. *J Neurosci*. 2000; 20:1831–1836. [PubMed: 10684884]
36. Nagerl UV, Mody I. Calcium-dependent inactivation of high-threshold calcium currents in human dentate gyrus granule cells. *J Physiol*. 1998; 509(Pt 1):39–45. [PubMed: 9547379]
37. Mattson MP, Rychlik B, Chu C, Christakos S. Evidence for calcium-reducing and excito-protective roles for the calcium-binding protein calbindin-D28k in cultured hippocampal neurons. *Neuron*. 1991; 6:41–51. [PubMed: 1670921]
38. Lopez-Meraz ML, Wasterlain CG, Rocha LL, Allen S, Niquet J. Vulnerability of postnatal hippocampal neurons to seizures varies regionally with their maturational stage. *Neurobiol Dis*. 2010; 37:394–402. [PubMed: 19879360]
39. Kurushima H, et al. Selective induction of DeltaFosB in the brain after transient forebrain ischemia accompanied by an increased expression of galectin-1, and the implication of DeltaFosB and

- galectin-1 in neuroprotection and neurogenesis. *Cell Death Differ.* 2005; 12:1078–1096. [PubMed: 15861185]
40. Kim D, et al. Deregulation of HDAC1 by p25/Cdk5 in neurotoxicity. *Neuron.* 2008; 60:803–817. [PubMed: 19081376]
41. Iyengar SS, et al. Suppression of adult neurogenesis increases the acute effects of kainic acid. *Exp Neurol.* 2015; 264:135–149. [PubMed: 25476494]




Figure 1. Epigenetic regulation of *Calb1* in the hippocampus of APP and pilocarpine mice
(a) Regression analysis of the relationship between hippocampal calbindin protein immunoreactivity (IR) and seizure frequency in 2-4 month-old APP mice (n=14 mice). IR values were transformed via natural log. **(b)** Representative images of hippocampal calbindin and Δ FosB IR in NTG and APP mice. Scale bar = 250 μ m. **(c)** Regression analysis of calbindin and Δ FosB IR in APP mice (n=28 mice). NTG data points are also displayed (n=30 mice). **(d)** Binding of Δ FosB to the *Calb1* promoter in the hippocampus of NTG and APP mice (n=16 mice/genotype, $t_{30}=3.72$, *** $p=8.3\times 10^{-4}$). **(e)** Levels of histone 4 (n_{NTG}=9 mice, n_{APP}=8 mice, $t_{15}=-2.46$, * $p=0.026$) and histone 3 (n=8 mice/genotype, $t_{14}=0.21$, $p=0.84$) lysine acetylation on the *Calb1* promoter of NTG and APP mice. **(f)** Levels of *Calb1* histone 4 lysine 20 trimethylation (n_{NTG}=10 mice, n_{APP}=12 mice, $t_{20}=2.09$, * $p=0.049$), histone 3 lysine 9 dimethylation (n=7 mice/genotype, $t_{12}=0.31$, $p=0.76$), and histone 3 lysine 9 trimethylation (n_{NTG}=8 mice, n_{APP}=7 mice, $t_{13}=-1.38$, $p=0.19$) in NTG and APP mice. **(g)** Δ FosB bound to *Calb1* (n=4 mice/treatment, $t_6=3.4$, * $p=0.015$) and **(h)** *Calb1* histone 4 lysine acetylation (n=4 mice/treatment, $t_6=-1.94$, one-tail * $p=0.05$) 3 days after pilocarpine-induced status epilepticus versus saline control. **(i)** *Left*, representative high-magnification

images of FosB and calbindin IR in the DG of pilocarpine-treated mice with mild (<2 stage five convulsions) or severe (>2 stage five convulsions) seizures during status epilepticus. Scale bar = 50 μ m. *Right*, cell-by-cell regression analysis of FosB and calbindin IR in a pilocarpine-treated mouse (n=30 cells). **(j)** *Left*, high-magnification images of hippocampal FosB and calbindin IR in APP mice with varying severities of epilepsy. *Right*, cell-by-cell regression analysis of FosB and calbindin IR in an APP mouse (n=30 cells). Scale bar = 50 μ m. Arrowheads, granule cells double-labeled with both FosB and calbindin. Arrows, granule cells single-labeled with either FosB or calbindin. GCL, granule cell layer. ML, molecular layer. *ns*, non-significant. Data in panels (d-g) were analyzed using Student's t-tests. Error bars represent SEM.




Figure 2. FosB mediates transcriptional repression of *Calb1* expression and causes spatial memory deficits

(a,b) Representative images and quantification of FosB IR in the DG of wild-type mice that received bilateral hippocampal infusion of AAV carrying either FosB/eGFP (AAV-FosB) or eGFP alone (AAV-eGFP) ($n_{\text{eGFP}}=10$ mice, $n_{\text{FosB}}=8$ mice, $t_{16}=8.23$, $***p=3.83\times 10^{-7}$). eGFP expression is also displayed and can be observed in the cell bodies (GCL), axons (hilus), and dendrites (ML) of AAV-eGFP granule cells. Scale bars = 250 μm and 50 μm (*inset*). (c) Binding of FosB ($n=7$ mice/treatment, $t_{12}=2.36$, $*p=0.036$) and (d)

histone 4 lysine acetylation ($n_{\text{eGFP}}=6$ mice, $n_{\text{FosB}}=8$ mice, $t_{12}=-2.21$, $*p=0.047$) on *Calb1* in AAV-eGFP and AAV- FosB mice. **(e,f)** *In situ* hybridization of calbindin mRNA ($n=5$ mice/treatment, $t_8=-5.94$, $***p=3.44\times 10^{-4}$). Scale bar = 250 μm . **(g,h)** Calbindin protein IR ($n_{\text{eGFP}}=10$ mice, $n_{\text{FosB}}=8$ mice, $t_{16}=-4.46$, $***p=4\times 10^{-4}$) in DG granule cells of AAV-eGFP and AAV- FosB mice. In panel (g), arrows indicate FosB-expressing granule cells, and arrowheads indicate calbindin-expressing granule cells. Scale bar = 50 μm . **(i)** *Left*, object location test procedure. *Right*, performance of AAV-eGFP and AAV- FosB mice in the object location test (paired t-tests: AAV-eGFP, $n=10$ mice, $t_9=4.6$, $**p=0.0013$; AAV- FosB, $n=8$ mice, $t_7=1.24$, $p=0.25$). Data in panels (a-h) were analyzed using Student's t-tests. Error bars represent SEM.




Figure 3. Both blockade of FosB signaling and direct rescue of calbindin expression ameliorate spatial memory deficits in APP mice

(a) Object location test performance of NTG and APP mice treated with bilateral hippocampal infusion of AAV carrying either JunD/eGFP (AAV- JunD) or eGFP alone (AAV-eGFP) (paired t-tests: AAV-eGFP/NTG, n=8 mice, $t_7=2.9$, $*p=0.023$; AAV-eGFP/APP, n=9 mice, $t_8=0.55$, $p=0.6$; AAV- JunD/NTG, n=7 mice, $t_6=3.63$, $**p=0.01$; AAV- JunD/APP, n=9 mice, $t_8=5.84$, $***p=3.86 \times 10^{-4}$). (b) Histone 4 lysine acetylation on the *Calb1* promoter of NTG and APP mice treated with AAV-eGFP or AAV- JunD (n=6 mice/group; two-way ANOVA: genotype $F_{1,20}=3.07$ $p=0.095$, treatment $F_{1,20}=2.98$ $p=0.1$, interaction $F_{1,20}=7.73$ $p=0.012$; Tukey's HSD: AAV-eGFP/NTG vs. APP $*p=0.021$, AAV- JunD/NTG vs. APP $p=0.89$). (c,d) Quantification and representative images of calbindin IR in NTG and APP mice treated with AAV-eGFP or AAV- JunD (n=6 mice/group except AAV-eGFP/APP n=5 mice; two-way ANOVA: genotype $F_{1,19}=13.82$ $p=0.0015$, treatment

$F_{1,19}=0.58$ $p=0.46$, interaction $F_{1,19}=3.45$ $p=0.079$; Tukey's HSD: AAV-eGFP/NTG vs. APP $**p=0.0056$, AAV- JunD/NTG vs. APP $p=0.44$). In panel (d), corresponding images of FosB IR (middle row) and JunD/ JunD IR (bottom row) are also shown. Scale bar = 50 μm . (e,f) Quantification and images of calbindin IR in APP mice treated with either AAV carrying either CMV promoter-driven calbindin/eGFP (AAV-Calb1) or AAV-eGFP (n=8 mice/group; Student's t-test: $t_{14}=3.36$, $**p=0.0046$). In panel (f), corresponding images of FosB IR (right) are also shown. Scale bar = 50 μm . (g) Object location test performance of APP mice treated with AAV-eGFP or AAV-Calb1 (n=8 mice/group; paired t-tests: AAV-eGFP, $t_7=-0.45$, $p=0.67$; AAV-Calb1, $t_7=3.89$, $**p=0.0059$). Error bars represent SEM.




Figure 4. Increased hippocampal FosB expression corresponds with decreased calbindin expression in patients diagnosed with MCI, AD, or TLE

(a-d) Images, quantification, and regression analysis of FosB and calbindin IR in DG of postmortem control (CTL, n=6 patients), MCI (n=10 patients), and AD (n=10 patients) (FosB one-way ANOVA: $F_{2,23}=6.893$, $p=0.0045$; Tukey's HSD: CTL vs. MCI $*p=0.0153$, CTL vs. AD $**p=0.0045$; calbindin one-way ANOVA: $F_{2,23}=4.461$, $p=0.023$; Tukey's HSD: CTL vs. MCI $*p=0.045$, CTL vs. AD $*p=0.026$). In panel (a), numbers in parentheses represent MMSE scores. Scale bar = 100 μ m. (e-h) Regression analyses of FosB/calbindin

IR and MMSE performance in MCI and AD patients. **(i,j)** Representative images and regression analysis of FosB and calbindin IR in surgically resected DG from TLE (n=8 patients). Scale bar = 100 μ m. AU, arbitrary units. Additional control, MCI, AD and TLE patient information is provided in Supplemental Fig. 9. Error bars represent SEM.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript